You are here

  • Home
  • Archive
  • Volume 31, Issue Suppl 3
  • 185 ENGOT-en11/GOG-3053/KEYNOTE-B21: phase 3 study of pembrolizumab or placebo + adjuvant chemotherapy ± radiotherapy for high-risk endometrial cancer

Article metrics

Article menu

Download PDFPDF

Endometrial cancer
185 ENGOT-en11/GOG-3053/KEYNOTE-B21: phase 3 study of pembrolizumab or placebo + adjuvant chemotherapy ± radiotherapy for high-risk endometrial cancer
Free

 

Online download statistics by month:

Online download statistics by month: October 2021 to April 2024

AbstractFullPdf
Oct 202171023
Nov 202171014
Dec 202136011
Jan 20227008
Feb 20223809
Mar 202257019
Apr 202240015
May 202254021
Jun 20223406
Jul 20223007
Aug 202249014
Sep 20224207
Oct 20225907
Nov 20226109
Dec 20223809
Jan 20233306
Feb 20233906
Mar 202368011
Apr 202332011
May 20232405
Jun 202352012
Jul 202340014
Aug 202358012
Sep 20234808
Oct 202379019
Nov 202394029
Dec 20234806
Jan 20243204
Feb 202436019
Mar 202453036
Apr 202432010
Total15180387